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Objectives: The aim of this study was to investigate Jordanian physicians’ perception and attitudes toward generic
medicines and generic substitution. It also aimed to examine factors that affect physicians’ pattern of prescribing,
and to evaluate their opinion regarding future introduction of Electronic Prescribing (EP) in Jordan.
Methods: A cross-sectional descriptive study involving Jordanian physicians working in both public and private
sectors was undertaken, using a self-administrated anonymous questionnaire. Frequency tables, cross-tabulation
and chi square tests were used for data analysis. The response rate was 75.2% (n = 376/500).
Results: Cost was claimed to be an important factor in the prescribing decision for 69.1% of the Jordanian
physicians. The majority of physicians (77.4%) claimed that they often prescribe generic medicines. Jordanian
physicians predominantly welcomed the implementation of an EP and International Nonproprietary Name (INN)
prescribing systems with 92%, and 80.1% respectively. More than two thirds of the physicians (69.4%) accepted
generic substitution by pharmacists, with a significant association with their employment sector; physicians who
work in the private sector tended to oppose generic substitution compared with physicians who work in the public
sector. Physicians mostly (72.1%) opposed that generic substitution should only be allowed upon patient request.
Conclusions: Jordanian physicians have a positive attitude towards generic medications and high willingness and
acceptance of strategies that encourage generic utilisation such as EP, INN prescribing and generic substitution. All
these strategies would help reduce the high expenditure on medicines in Jordan. These findings would provide
baseline data to policy makers to develop a robust generic policy to achieve greater clinical effectiveness and
economic efficiency from medicines prescribing.
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The high health care expenditure on pharmaceutical prod-
ucts is becoming a challenging issue worldwide [1,2]. In
2007, the expenditure on drugs in Jordan exceeded US$
700 million, which accounted for around one-third of the
national health care budget. Moreover, these costs are be-
lieved to be higher than most countries that have similar
income calibre of Jordan [3].
In general, generic medicines are 20% to 90% cheaper
than the innovator medicine, and their utilisation repre-
sents a well-established strategy for controlling health care
expenditures [4-6]. A generic medicine is defined as a me-
dicinal product which is identical in its active ingredient* Correspondence: fdahiyat@hotmail.com
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lent to an originator medicine, whose granted patent pro-
tection has expired [7,8]. Generic medicines are generally
marketed under the non-proprietary name or could be
marketed as branded generics [9], as in the case of Jordan
where 97% of generic medicines are branded [10]. Public
and private third party payers and health care authorities
increasingly encourage or mandate the use of generics
through measures such as generic prescribing and generic
substitution [11-15]. In 2002, a circular from the Jordanian
Ministry of Health required doctors in public hospitals
and health clinics to prescribe generically [16].
The prescribing behaviour of physicians is considered to
be crucial for generic utilisation as they determine
whether their patients need originator drugs or generic
drugs [17]. A generic medicine may not always be suitableral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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role in influencing the physicians ‘prescribing behaviour
such as the “trust” and the “quality image” of the pharma-
ceutical company [19]. Physicians’ prescribing behaviour
can also be influenced by pharmaceutical companies
through a variety of incentives such as high-end education
programs or even some cash payment for prescriptions
[20]. In addition, free samples and gifts that include finan-
cing for domestic and international conference participa-
tion, travel and accommodation, medical education,
meals, honoraria and small gifts like pens can also influ-
ence prescribing. However, one cannot state that physi-
cians prescribe only on the basis of the rewards that they
receive from the company, but the rewards certainly help
physicians to remember the company brands [21,22].
Therefore, these incentives may indirectly affect the
patients, by encouraging them to use higher priced origin-
ator products instead of equally effective, lower-cost
generics [23].
Patients’ requests and preference play a vital role in
prescribing behaviour and according to previous re-
search when physicians do not comply with patient re-
quests, patients are less satisfied with their physician
visit [24,25].
Globally, physicians are much more sensitive to argu-
ments about a drug's efficacy than about its price
[26,27]. The effect of price and cost of medicine was
found to be insignificant on physician prescribing behav-
iour [28]. As they do not bear the full cost of the pre-
scribed drug, or they possess limited information about
cost and prices of medicines [29-31].
An efficient source of information about the cost
of medicines is believed to be through E-prescribing
system (EP), where prescriptions are generated within
e-prescribing systems and are transmitted electronically
to pharmacies through a secure network between phys-
ician office and community pharmacies [32]. This in-
volves direct computer-to-computer transmission of
prescriptions [33]. EP not only reduce health care costs
by avoiding adverse drug events and substitution to less
expensive medicine, but also enables the prescribers to
check patients’ health plan or insurance coverage at the
point of care. Additionally it offers physicians a powerful
tool to manage their patients’ medication in a safe and
efficient way. EP can enhance patient safety and medica-
tion compliance , improve prescribing accuracy and effi-
ciency, decrease pharmacy costs, reduce phone calls
between pharmacists and physicians, reduce data entry,
expedite prescription refill requests compared to paper-
based prescribing, and eliminate handwriting interpret-
ation errors [34,35].
It was reported that 7000 patients die every year in the
US due to medication error [36], including error caused
by illegible handwritten prescriptions. As a result, theuse of EP was promoted [37]. In another study which
was conducted in a UK hospital, there was a significant
reduction in both pharmacists' interventions and pre-
scribing errors following the introduction of EP. Inter-
ventions were reduced from 3.0% on all medication
orders to 1.9%, and errors from 3.8%to 2.0% [38]. More-
over, a previous study found that physicians using an EP
system increased their generic substitution rate by 15%
and increased generic prescribing by more than 8% [39].
In Jordan, despite the continuous increase in pharma-
ceutical expenditure, a pharmaceutical policy focusing
on the promotion of generics utilisation has never been
developed. Therefore, the aim of this paper was to inves-
tigate physician perception and attitudes toward generic
medicines and generic substitution, to examine factors
that affect this pattern of prescription, and to evaluate
their opinion regarding future introduction of EP in
Jordan. The findings from this study would provide a
baseline data for the introduction of a robust generic
policy and eventually the use of more efficient measures
to control pharmaceutical expenditures.
Methods
In this cross sectional study a questionnaire was carried
out to collect data from Jordanian physicians working in
private or public sectors, as physicians who are working
in the public sectors are not allowed to work private
sector, in order to measure physicians’ prescribing be-
haviour, and their perceptions towards generic medicines
and issues pertaining the use of generics in Jordan.
Anonymity of respondents was preserved in the study,
as names of participants were not included.
The questionnaire was tested for face and content val-
idity by two experts. The wording of the survey was fur-
ther revised after pilot testing with ten physicians.
Moreover, some questions were presented and explained
in better way. There are four sections in the question-
naire. The first section evaluates the prescribing behav-
iour of the responding physicians. The following section
was exploring physicians’ perception towards generic
medicines. The third section measures physicians’ opin-
ion regarding issues pertaining the use of generics in
and the introduction of EP in Jordan. The last section
characterised the respondents’ demographics. The re-
sponses were framed in different type such as single,
multiple (participants were allowed to choose more than
one answer) and four point likert scale (1 = strongly
disagree, 2 = disagree, 3 = agree and 4 = strongly agree).
According to the Jordanian Medical Association, the
entire sample population is 17000 physicians; From the
500 questionnaires which were distributed, 376 ques-
tionnaires were collected from physicians in private and
public sectors and included in this study which gives a
response rate of 75.2%. This is a representative sample
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error and 95% confidence level.
The participation of physicians was strictly voluntary.
The informed consent of the participants was obtained
and no personal data of the participants were reported.
Data was collected from 2nd June 2012 to 15st July
2012. All the collected data was entered into PASW®
18.0 for descriptive analysis using frequency and cross-
tabulation and chi square tests. This study was ap-
proved by the Research Ethics Committee of Kingston
University, London.
Results
Demographic characteristics of responding physicians
A total of 376 responses were included, the basic demo-
graphic of the responding physicians is summarised in
Table 1. The sample was distributed between male
(240, 63.8%) and female (136, 36.2%). The modal age of
the responding physicians were between 30 years and
40 years. Respondents had different years of experience
in practicing medicine; the modal years of experience
were from 6–10 years. Regarding the employment sec-
tor, almost the same number of responses was collected
from physician working in private and public sectors
(Table 1).
Prescribing behaviour
When assessing the rank of the factors that may influ-
ence physicians’ decision when prescribing a medicine,
















21 and above 35 (9.3)
Employment Sector
Private 180 (47.9)
Public 196 (52.1)a medicine prescribed with a mean of 1.04. The second
factor was the dosage form and daily recommended dose
with a mean rank of 2.52, the cost of medicine was the
third factor affecting physicians decision with a rank of
3.57, the forth factor was patient preference with a mean
rank of 4.00. However, the fifth rank was availability as
a generic and the sixth rank was for country of origin of
a medicine with means of 4.87 and 5.25 respectively
(Figure 1).
The physicians’ prescribing behaviour was evaluated,
the majority of the respondents (86.7%) use international
treatment guidelines to justify their prescribing decision.
An almost equal percentage (57.4% and 54.5%) use local
guideline and local protocols or medical journals publi-
cation and online databases respectively. Conferences
and pharmaceutical sales representatives were used by
37.2% and 12% of the physician respectively in order to
justify their prescribing decision. Few responders (2.7%)
justify their decision by other reasons such as their own
experience and patient clinical history.
Cost of medicine
The physicians were asked about the importance of cost
in their prescribing decision, 58.5% of them believed that
the cost is important, 10.6% believed that the cost is
highly important, whereas 30.9% of the physicians be-
lieved that the cost is not important at all.
Further analysis showed that the community pharma-
cists were the main source for physicians in order to get
the information about cost of medicine as mentioned by
77.1% of the responders. The second source used by
65.4% of responding physician was pharmaceutical sale
representatives, while Jordan food and drug administra-
tion (JFDA) website was used only by 20.2% of physi-
cians. Other source used was the patients themselves
according to 9.3% of responders.
Current generic prescribing
When assessing how often physicians prescribe generic
medicine instead of originator brand in their current
practice, only 1.3% of the participants stated hardly ever
and 21.3 stated % rarely. However, 62.8% of the physi-
cians often prescribe generic and 14.6% of the physicians
very often prescribe generic medicine instead of an ori-
ginator brand. A chi-square statistic was calculated to
examine if there is a relation between the employment
sector of the responders and whether or not they pre-
scribe generic medicines in their daily practice. The test
was found to be statistically significant; the value of chi
square is 54.580 with a P value < 0.05. Physicians work-
ing in public sectors are more likely to prescribe generic
medicines.
When physicians were asked about how often they
write their prescriptions using the International Non-
Figure 1 Rankings of the means for factors that in fluence prescribing behaviour of Jordanian physicians.
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very often. An equal percentage (43.9%) used INN either
often or rarely, and 8.2% hardly ever used INN.
There was a significant correlation between physicians’
employment sector and whether or not they write their
prescription using the INN. The value of chi square is
28.195 with a P value < 0.05. Physicians working in pub-
lic sectors are more likely to prescribe using INN.
Perceptions about generic substitution
When assessing the physicians’ perception on generic
substitution, 96% of responding physicians agreed
that the ability to perform generic substitution will
ensure prompt availability of medications to the pa-
tient and that generic substitution will increase the
use of locally produced medicines. Further analysis
found that 92.1% of the physicians perceived that
generic substitution offer significant cost advantage to
the patient. In addition, 74.7% believed that such a
practice will allow pharmacists to select the most af-
fordable drug to a patient (Table 2).
Giving community pharmacists in Jordan generic sub-
stitution right was agreed by 61.5% of the responders.
On the other hand, 72.1% of the physicians opposed that
generic substitutions practice should be allowed upon
patient request only (Table 2).
When assessing physicians’ general opinion regarding
generic substitution by community pharmacists, around
half of them (49.2%) accepted generic substitution in
most cases as there are some situations where it is not
appropriate and 20.2% accepted it in all cases where a
generic is available, Interestingly, 30.6% do not accept
generic substitution by pharmacists at all (Figure 2).
There was a significant correlation between physician’
employment sector and whether or not they accept gen-
eric substitution. The value of chi squares was 11.87
with a P value < 0.05. Physicians working in public sectortended to accept generic substitution more compared
with physicians working in private sector.
When physicians who accepted the generic substitu-
tion in the previous question either in most or in all
cases were asked about preferred generic substitution
practice, 45.8% of them believed that pharmacists must
consult them when performing generic substitution.
However, 42% of the responders preferred that pharma-
cists only consulted them if they are substituting certain
group of drugs (e.g., narrow therapeutic index). Only
12.2% of the physicians who accepted generic substitu-
tion in most or all cases believed that pharmacists
should be allowed to perform generic substitution
without consulting the prescribing physician (Figure 3).
There was a significant correlation between physicians’
employment sector and the standard of practice, the
value of chi squares is 10.85 with a P value <0.05. By
reviewing the cross table, physicians working in public
sector believe that pharmacists should allowed to per-
form generic substitution without consulting them.
Perceptions regarding future introduction of EP in Jordan
Nearly all of the responding physicians (98.7%) agreed that
developing a computerised system which includes import-
ant information about drugs such as: medicines interaction,
contraindications and cost, would improve the prescribing
process. The implementation of an EP system would result
in a more efficient prescribing and dispensing process ac-
cording to 92% of the responders (Table 2).
However, majority of physicians (80.1%) agreed to the im-
plementation of a prescribing system based on INN (Table 2).
The majority (97.3) also believed that standard guide-
lines on generic substitution for both physicians and phar-
macists should be implemented. Furthermore, 90.7%
agreed that quality use of generic medicines among Jor-
danian consumers can be achieved if both physicians and
pharmacists work together.
Table 2 Jordanian physicians ’ responses to four point likert scale questions exploring perceptions towards generic
medicines and issues pertaining the use of generics in Jordan
Survey questions/Statement Frequency (%)
Strongly disagree Disagree Agree Strongly agree
Generic substitutions will increase the use of locally produced medicines. 5 (1.3%) 10 (2.7%) 276 (73.4%) 85 (22.6%)
Ability to perform generic substitution will ensure prompt availability of
medications to the patient
0 (0.0%) 15 (4.0%) 216 (78.7%) 65 (17.3%)
Generic substitution offer significant cost advantage to the patient. 0 (0.0%) 30 (8.0%) 271 (72.1%) 75 (19.9%)
Generic substitution will allow pharmacists to select to select the most
affordable drug to a patient.
5 (1.3) 90 (23.9%) 256 (68.1%) 25 (6.6%)
Developing a computerized system which includes important information
about drugs such as: medicines interaction, contraindications and cost,
would improve the prescribing process
0 (0.0%) 5 (1.3%) 180 (47.9%) 191 (50.8%)
Implementing an electronic prescription service would result in a more
efficient prescribing and dispensing process. 0 (0%)
30 (8.0%) 241 (64.1%) 105 (27.9%)
Standard guidelines on generic substitution process to both physicians
and pharmacists should be implemented.
0 (0.0%) 10 (2.7%) 291 (77.4%) 75 (19.9%)
Quality use of generic medicines among Jordanian consumers can be
achieved if both physicians and pharmacist work together.
0 (0.0%) 35 (9.3%) 256 (68.1%) 85 (22.6%)
It is feasible to implement prescribing system based on International
Non-priority Name (INN).
5 (1.3%) 70 (18.6%) 241 (64.1%) 60 (16.0%)
Community Pharmacist in Jordan should be given generic substitution right. 25 (6.6%) 120 (31.9%) 160 (42.6%) 71 (18.9%)
Generic substitution should be allowed only at patient request. 80 (21.3%) 191 (50.8%) 85 (22.6%) 20 (5.3%)
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The purpose of this study is multifaceted. We wanted to
investigate physicians’ opinions about substituting generic
medications for brand name drugs and their prescribing
behaviour and opinions regarding the introduction of an
EP system.
In general, physicians were concerned about the effi-
cacy of a drug rather than its price when making pre-
scribing decisions [40,29]. In the current study, clinical
effectiveness was the most important factor that influ-
enced the prescribing behaviour of physicians in Jordan.
The second factor was the pharmaceutical dosage form
and recommended daily defined dose, with the cost
of the prescribed medicine being the third important
factor. These results are consistent with the results of aFigure 2 General opinion regarding generic substitution by
community pharmacists.previous study that measured the prescribing behavior
of physician in Greece and Cyprus [41].
Previous studies considered the cost as an important
factor in physicians prescribing behaviour. In a study
that was held in America, the cost was an important
factor when prescribing especially for uninsured patients
[42]. Additionally, results from a qualitative study in
Denmark showed that drug cost was considered an im-
portant factor influencing prescribing decisions [5].
Moreover, a study in Greece and Cyprus found that 60%
of the physicians consider the cost as important [41].
In this study the views of physicians were consistent
with these studies, 69.1% of them claimed that the cost
is important in their prescribing decision. There was aFigure 3 Generic substitution preferred practice according to
physicians who accepted it in most or all cases.
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cost while prescribing and physician’s employment sec-
tor. Physician working in the public sector were more
likely to consider the cost when prescribing than their
counterparts in the private sector.
From the findings, physicians use international treat-
ment guidelines as well as local guideline and local proto-
cols as main sources to justify their prescribing decisions.
Medical journals publication and online databases come
after and then conferences. However, pharmaceutical sales
representatives were claimed to be of least importance.
This contradicted the previous studies in which pharma-
ceuticals sale representatives were more important sources
of information in New Zealand [43], Denmark [44] and in
Nigeria [45].
Only 9.3 % of the physician reported that patient com-
munication was the source of medicines’ cost. Patients
hardly ever communicate with their physicians about
medication choices and out-of-pocket costs of medica-
tions [46,47].
One of the most important findings of this study is that
physicians seem to be open to prescribing generic medi-
cines; the majority of the responders 77.4% claimed that
they often prescribe generic medicines. However, only
47.9% of the Jordanian physicians claimed to be writing
their prescriptions currently using the International Non-
priority Name (INN). This variation in percentage could
be due to the fact that about (97%) of the locally produced
medicines are branded generic [10]. This indicates, how-
ever, that physicians in Jordan hold a positive view about
generic medicines. This was similar to a study in Malaysia
where the majority of the physicians (85.1%) claimed that
they actively prescribed generic medicines in their practice
[48]. On the other hand, in Greece, only one of four physi-
cians (24.8%) prescribed generic medicines [49].
This study found that if a prescribing system based on
the INN was implemented, 80.1% of the physicians are
willing to use it. This was similar to a French study,
where the majority of physicians (76.2%) declared that
they were willing to write their prescriptions using INN
[50]. Using an INN prescribing system not only would
minimise confusion but also would improve patient ac-
ceptability of generic medicines.
Almost all Jordanian physicians believed that devel-
oping a computerised EP system which includes im-
portant information about drugs such as; medicines
interaction, contraindications and cost, would improve
the prescribing process and result in a more efficient
prescribing and dispensing process. Implementing such
a prescribing system not only would support improved
medication adherence [51], but also reduce cost through
generic utilisation.
Majority of Jordanian physicians (49.2%) accepted gen-
eric substitution in most cases as there are some situationswhere it is not appropriate (e.g. for narrow therapeutic
index drugs) and 20.2% accepted it in all cases where a
generic is available. Whereas, 30.6% did not accept generic
substitution by pharmacists at all. On the other hand,
the results from a previous study in America showed
that 78% of physician supported generic substitution in
most cases, 17 % supported the substitution in all cases
where generic is available and only 5% do not support
substitution at all [52].
Physicians mostly (72.1%) opposed that generic sub-
stitution should only be allowed upon patient request.
Despite the widespread belief that medical decisions
are sensitive to patients' expectations [53], the choice
of prescribed drugs appears to result essentially from
the physician's own decision-making process [54].
Nevertheless, 61.5% agreed to give the pharmacist the
substitution right.
It was observed statistically that there is a significant as-
sociation between physicians’ acceptability for generic sub-
stitution and their employment sector; physicians who
work in the private sector tended to oppose generic sub-
stitution compared with physicians who work in the pub-
lic sector. This finding was similar to previous studies
in which private physicians were 50–80% more likely to
oppose substitution, as they might have stronger brand-
name loyalty. This could be due to private sector physi-
cians being less restricted to participate in educations and
conferences paid for by pharmaceutical firms, or to per-
form paid assignments for them compared to public phy-
sicians as there is many rules restricting them from such
participation [55]. Therefore, private physicians’ prescrib-
ing behaviour may be influenced by pharmaceutical com-
panies through a variety of incentives such as high-end
education programs or even some cash payment for
prescriptions [20]. These incentives may indirectly
affect the patients, by encouraging them to use higher
priced originator products instead of equally effective,
lower-cost generics [23].
There are many benefits for generic substitution to be
implemented in Jordan. It will ensure prompt availability
of medications to the patients, and it will support the
local industry by increasing the use of locally produced
medicines. Generic substitution will also offer significant
cost advantage to the patient by allowing the selection of
the most affordable drug to a patient.
The finding from this study suggested that, in order to
increase the generic utilisation in Jordan, standard guide-
lines on generic substitution process to both physicians
and pharmacists should be implemented. Furthermore,
the results highlighted that the quality use of generic med-
icines among Jordanian patients can be achieved if both
physicians and pharmacists worked together.
Jordanian physicians had stated that there is a need for a
standard guideline on generic substitution. The adoption
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cists on how and when to perform generic substitution for
their patients or by introducing legislation for compulsory
generic substitution wherever appropriate would further
encourage the use of generic medicines and maintain ac-
cessibility and affordability of medicines.[50,56].
Conclusion
The findings from this study showed the positive
attitude of Jordanian physicians towards generic medica-
tions and their high willingness and acceptance of strat-
egies that encourage generic utilisation in Jordan such as
generic substitution, INN prescribing and EP. All these
strategies would help reduce the high expenditure on
drugs in Jordan which accounted for around one-third
of the national health care budget [3].
These insights will help policy makers in Jordan to de-
velop a robust generic policy which could be used to
achieve to greater clinical effectiveness and economic ef-
ficiency from drug prescribing.
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